<DOC>
	<DOCNO>NCT02484677</DOCNO>
	<brief_summary>Docetaxel , Cisplatin , 5-Fluorouracile ( =TPF ) mainstay treat head neck cancer , elderly fragile patient often preclude risk severe toxicity associate protocol . DPD ( Dihydro Pyrimidine Dehydrogenase ) deficiency pharmacogenetic syndrome responsible severe/lethal toxicity show 5-FU ( 5-Fluorouracile ) -treated patient , institute develop strategy routine determination Dihydro Pyrimidine Dehydrogenase ( DPD ) status prior start give 5-FU roughly adapt drug dosage accord Dihydro Pyrimidine Dehydrogenase ( DPD ) status . This project aim develop Bayesian strategy individualize 5-FU dose reach target exposure area curve ( AUC ) . To end , 100 patient head neck cancer schedule Docetaxel , Cisplatin , 5-Fluorouracile ( =TPF ) regimen include .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacogenetics-based Adaptive Dosing 5-fu ( 5-Fluorouracile ) Head &amp; Neck Cancer Patient Undergoing Docetaxel , Cisplatin , 5-Fluorouracile ( =TPF ) Therapy</brief_title>
	<detailed_description>Crop plasma exposure 5-FU ( 5-Fluorouracile ) around predefined target area curve 30 ( AUC30 ) patient head neck cancer treat Docetaxel , Cisplatin , 5-Fluorouracile ( =TPF ) protocols correlate adaptive Bayesian procedure tolerability . - Develop population die group 20 patient pharmacokinetic study carry - Evaluate obtain effective concentration 5-FU context Docetaxel , Cisplatin , 5-Fluorouracile ( =TPF ) protocol adapt Bayesian procedure . - Compare recommendation term dosage adjustment Bayesian approach recommendation simplify graphical approach . - Test measure Dihydro Pyrimidine Dehydrogenase ( DPD ) activity Dihydrouracil/Uracile ( UH2 / U ratio ) co-variable adjustment 5-Fluorouracile ( 5-FU ) regimens Pharmacogenomics/Pharmacokinetic ( PGx / PK ) model . - Evaluate prototype urinary dipstick early detection toxicity assay marker Dihydro Pyrimidine Dehydrogenase ( DPD ) activity . - Assess cost-benefit dosage targeting , term reduction result cost management chemotherapy-induced toxicity .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Age &gt; 18 â‰¤ 80 year . Squamous cell carcinoma head neck ( oral cavity , oropharynx , hypopharynx , larynx , nasopharynx ) . Locally advanced stage ( III , IVa IVb ) . The patient must receive information note signing informed consent , well spent multidisciplinary meeting treatment TPF ( Docetaxel , Cisplatin , 5Fluorouracile ) induction chemotherapy propose . Performance Status le equal 2 ( WHO performance index ) . The patient must affiliate social security scheme follow one participating center . Patients polymorphonuclear neutrophil great equal 1000 / mm3 , platelet great equal 100 000 / mm3 , hemoglobin great equal 8 g / dl , transaminases less equal 1.5 time normal , total bilirubin equal 1.5 time normal creatinine clearance upper equal 50 ml / min Modification Diet Renal Disease ( MDRD ) Satisfactory heart function Patients must able submit rhythm visit , treatment plan , laboratory balance study procedure . Patient &gt; 80 year . Patients uncontrolled infection could compromise participation study . Patients serious concomitant disease / uncontrolled could compromise participation study . Patients serum bilirubin &gt; limit normal / Alanine Transaminase ( ALAT ) Aspartate Transaminase ( AST ) 3.5 time limit normal alkaline phosphatase great 6 time limit normal . Cardiovascular disease clinically significant cardiovascular disorder judgment investigator , , limit uncontrolled hypertension , congestive heart failure The New York Heart Association ( NYHA ) classification &gt; III ) , unstable angina , myocardial infarction 6 month prior treatment , uncontrolled arrhythmia , chronic liver renal disease , severely impaired lung function . Disorders significant acute gastrointestinal recent major symptom diarrhea , Crohn 's disease , malabsorption syndrome diarrhea Common toxicity Criteria Adverse Events ( CTCAE ) grade &gt; 1 whatever aetiology . Performance Status / laboratory test incompatible chemotherapy use cisplatin , docetaxel 5fluorouracile ( 5FU ) Inability submit medical monitoring test geographical reason , family , social psychological . Patients refuse participate biological assessment . Persons deprive liberty guardianship . Pregnant woman likely time enrollment breastfeed . Free , informed sign obtain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>